2026 Top 7 Canine Oncology and Chemotherapy Medications in Canada

Palladia is a veterinary-labeled, oral tyrosine kinase inhibitor that emerged as the clinical leader for treating canine mast cell tumors due to its tumor-directed mechanism and strong evidence base in dogs; its targeted action and convenience of oral dosing set it apart from broad-spectrum cytotoxics on this list. Compared with Masivet, Palladia is often preferred for specific mast cell tumor indications and has a well-established veterinary safety profile, while it is more costly than generic injectable cytotoxic drugs like Cyclophosphamide but offers a favorable trade-off for chronic, targeted management.

Masivet is a veterinary tyrosine kinase inhibitor with a slightly different kinase inhibition profile than Palladia, positioning it as a competitive market leader for certain canine mast cell tumors and other malignancies where alternative target engagement or cost considerations matter. Financially, Masivet can be a more affordable targeted option in some markets and provides a complementary technical profile to Palladia, while remaining distinct from injectable cytotoxic agents and supportive drugs like Cerenia or Ondansetron that address treatment side effects rather than tumor drivers.

Elspar is a long-established injectable enzyme therapy used primarily in lymphoid malignancies in dogs; its unique mechanism of depleting asparagine delivers rapid antitumor effects and makes it a go-to option in combination protocols where immediate cytotoxic impact is needed. Technically it complements alkylating agents such as Cytoxan and steroid adjuncts like Dexamethasone, and although Elspar can be pricier per dose than generic antiemetics, its niche indication and rapid onset justify its place in veterinary oncology protocols.

Cerenia is the veterinary-formulated antiemetic of choice for dogs receiving chemotherapy because it was developed and labeled specifically for canine use, providing predictable control of nausea and vomiting compared with human antiemetics on this list. While not an antineoplastic, its role in maintaining quality of life and enabling continuation of treatments such as Cytoxan or Elspar differentiates it from Ondansetron by offering a veterinary-focused dosing, safety data set, and often streamlined reimbursement in clinic formularies.

Ondansetron injectable (marketed under leading human brands and generic producers) is a widely used serotonin 5-HT3 antagonist that serves as an economical, broadly available antiemetic adjunct in canine oncology, particularly where cost or formulary constraints limit access to veterinary-labeled products. Compared with Cerenia, ondansetron is often less expensive and globally available as generics, but it lacks the same breadth of veterinary-specific labeling and palatability/administration advantages of products designed for dogs.

Cytoxan is a well-established alkylating agent and a backbone chemotherapy for many canine malignancies, prized for its broad cytotoxic efficacy, oral and injectable formulations, and cost-effectiveness relative to newer targeted agents. Financially and technically, Cytoxan offers an economical core option for multi-agent protocols and is often used in combination with enzyme therapies like Elspar or adjunctive corticosteroids such as Dexamethasone, though it carries the class risks typical of cytotoxic chemotherapy.

Dexamethasone injection is a potent corticosteroid widely used in veterinary oncology for its anti-inflammatory, antiemetic adjunctive, and lympholytic effects, making it an inexpensive and versatile companion to both targeted therapies like Palladia and cytotoxic drugs like Cytoxan. Its low cost and universal availability make it a practical choice for symptom control and protocol support, though it serves a supportive rather than primary antineoplastic role compared with agents such as Elspar or the TKIs listed above.